MSH2 and cancer: We here report prospectively observed, cumulative incidences of cancer in path_MLH1 and path_MSH2 carriers with truncating versus predicted missense and non-canonical aberrant splicing pathogenic variants to explore the hypothesis that carriers of truncating variants have higher cancer incidence.